Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderately to severely active ulcerative colitis in adults.
Commercial arrangement
There is a simple discount patient access scheme for upadacitinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. ...
Desde la publicación de la primera edición de la Guía en 2013, se ha generado mucha información en torno al tratamiento de la colitis ulcerosa, y se han introducido nuevos fármacos y protocolos de actuación. La práctica clínica ha variado substancialmente, lo que justifica nuevas aproximaciones y...
This guideline covers the management of ulcerative colitis in children, young people and adults. It
aims to help professionals to provide consistent high-quality care and it highlights the importance
of advice and support for people with ulcerative colitis....
Bressler, B;
Marshall, J. K;
Bernstein, C. N;
Bitton, A;
Jones, J;
Leontiadis, G. I;
Panaccione, R;
Steinhart, A. H;
Tse, F;
Feagan, B.
BACKGROUND & AIMS:: The medical management of ulcerative colitis (UC) has improved through the development of new therapies and novel approaches that optimize existing drugs. Previous Canadian consensus guidelines addressed the management of severe UC in the hospitalized patient. We now present consensu...
